middle.news
EBOS Group Surges 7.1% in Underlying EBITDA, Confirms FY25 Growth Path
6:51am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
EBOS Group Surges 7.1% in Underlying EBITDA, Confirms FY25 Growth Path
6:51am on Monday 2nd of June, 2025 AEST
Key Points
Underlying EBITDA up 7.1% excluding Chemist Warehouse Australia contract
Revenue growth of 9.5% ex-CWA driven by Healthcare and Animal Care segments
Strong cash flow generation with $205 million underlying cash from operations
Strategic acquisitions in Southeast Asia completed, increasing Transmedic stake to 100%
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Ebos (ASX:EBO)
OPEN ARTICLE